On October 12, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, reported that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference: Tumor Immunology and Immunotherapy, to be held on October 21-24, 2022 as an in-person event in Boston, Massachusetts (Press release, Kineta, OCT 12, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-present-anti-cd27-agonist-preclinical-program-at-aacr-conference-on-tumor-immunology-and-immunotherapy [SID1234621989]). Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!